Mitochondrial-Derived Peptide • Discovered 2001

Humanin: The Neuroprotective Mitochondrial Peptide

📄 8 PubMed citations

Last updated: November 2026

Humanin is the first discovered mitochondrial-derived peptide: a 24-amino acid sequence encoded within the mitochondrial genome. Identified in 2001 as a neuroprotective factor, it blocks apoptosis and reduces oxidative stress in cell studies, improves insulin sensitivity in rodents, and its circulating levels decline with age.

24
Amino Acids
in Sequence
2001
Year
Discovered

Track your vials and inventory on paper

Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →

The 2001 Discovery Story

Found in a functional screen for factors that rescue neurons from Alzheimer's-linked cell death, Humanin changed how we think about mitochondria.

In 2001, Hashimoto and colleagues at Keio University School of Medicine in Tokyo were screening a cDNA library from the occipital lobe of an Alzheimer's patient. A short, previously unknown sequence (later traced to an open reading frame in the mitochondrial 16S rRNA region) completely protected neurons from amyloid-beta-induced cell death. They named it Humanin.

🧬
mtDNA Origin

Humanin is encoded within the 16S rRNA gene of the mitochondrial genome, the same genome that manages cellular energy production. It is the first known peptide derived from mitochondrial DNA. An identical open reading frame also exists in the nuclear genome; Guo et al. (2003) speculated that Humanin arose in mitochondria and moved to the nucleus.

🛡️
Original Finding: Neuroprotection

The Hashimoto lab found that synthetic Humanin at micromolar concentrations, and its S14G analog at nanomolar concentrations, prevented neuron death triggered by familial Alzheimer's disease genes (APP, PSEN1, PSEN2) and amyloid-beta in cell cultures.

📡
Secreted Signal

Humanin is not just intracellular. In the original study it was secreted into the culture medium (Hashimoto et al., 2001), and it circulates in blood. Mitochondrial-derived peptides like it are described as mitochondrial hormones (Lee et al., 2016).

🔬
Found in Human Circulation

Humanin is detectable in human circulation, and circulating levels are lower in older adults (Muzumdar et al., 2009). This opened the door to studying it as both a biomarker and a potential therapeutic target.

How Humanin Works

Humanin operates through multiple pathways: blocking cell death, reducing oxidative stress, and modulating growth factor signaling.

🔐
Anti-Apoptotic: BAX Inhibition

Humanin binds the pro-apoptotic protein BAX and prevents it from moving from the cytosol to mitochondria, and in vitro it suppressed cytochrome c release from isolated mitochondria (Guo et al., 2003).

⚡
JAK2/STAT3 Activation

Humanin's protection against Alzheimer's-related neurotoxicity runs in large part through activation of the JAK2/STAT3 signaling axis, which a 2009 review calls a major transducer of its neuroprotective activity (Chiba et al., 2009).

🧪
IGF-1 / IGFBP-3 Modulation

Humanin binds IGFBP-3, a protein that regulates IGF activity, without blocking IGF-1 from binding IGFBP-3; the interaction can either add to or oppose IGFBP-3's effects on cell survival depending on cell type (Ikonen et al., 2003).

🌿
Oxidative Stress Reduction

In cell studies, Humanin reduced reactive oxygen species (ROS) and cell death under oxidative stress; in human aortic endothelial cells, pretreatment cut oxidized-LDL–induced ROS and apoptosis (Bachar et al., 2010).

🔄
Insulin Sensitization

In rodent studies, Humanin improved insulin sensitivity through hypothalamic STAT-3 signaling; its effect on liver insulin action was centrally mediated rather than direct (Muzumdar et al., 2009).

🫀
Vascular Cell Protection

Humanin is expressed in the endothelial lining of human blood vessels, and in cultured endothelial cells it reduced oxidized-LDL–induced apoptosis (Bachar et al., 2010).

Humanin levels drop with age.

Circulating Humanin was decreased with age in both humans and mice (Muzumdar et al., 2009). In that study's human data, plasma Humanin was about 40% lower at ages 81–110 than at ages 45–65 (roughly 800 vs 1,400 pg/mL, Figure 8B). People under 45 were not sampled, so the size of any decline from young adulthood is unknown.

🏋️
Metabolic Health Link

The authors of the 2009 study proposed that the age-related decline in Humanin could play a role in age-related diseases, including type 2 diabetes and Alzheimer's disease (Muzumdar et al., 2009). That is a hypothesis, not a tested result.

What the Research Shows

Preclinical evidence comes from cell and animal models of Alzheimer's disease and metabolic disease. Human data is limited to observational measurements: circulating levels and staining of blood-vessel tissue.

⚠️ Preclinical Research Stage

The majority of Humanin research consists of cell culture and animal studies. No human intervention data has been published in the sources cited here, and no large human clinical trials have been completed. Findings should not be extrapolated to clinical recommendations.

Alzheimer's Disease Research

Amyloid-Beta Toxicity Reduction
Neuronal cell death blocked in Aβ1-43 treated cultures (Hashimoto et al., 2001)
Cell study
Cognitive Function in Mouse AD Models
Synthetic analog S14G-humanin (HNG), given intraperitoneally to 9-month-old plaque-bearing mice, improved cognitive deficits (Zhang et al., 2012)
One mouse study
FAD Gene Protection (PSEN1/PSEN2/APP)
Protection from familial Alzheimer's genes in cell models (Hashimoto et al., 2001)
Dose-dependent

Metabolic Syndrome Research

Insulin Sensitivity Improvement
Central (hypothalamic) STAT-3–mediated insulin sensitization in rodents (Muzumdar et al., 2009)
Rodent study
Blood Glucose Lowering
A single dose of a potent Humanin analog lowered blood glucose in Zucker diabetic fatty rats (Muzumdar et al., 2009)
Rodent study

Additional Protective Effects

Oxidative Stress Reduction
Reduced oxidized-LDL–induced ROS in human endothelial cells (Bachar et al., 2010)
Cell study

Safety Considerations

Human safety data is sparse, and the animal studies cited here were not designed as toxicology studies. Risk assessment is extrapolated from animal and cell models.

⚠️ No Established Human Safety Data

Humanin has no completed Phase 2/3 human clinical trials. All safety information comes from animal studies and in vitro data. Do not use without consulting a qualified physician.

🧪
Animal Studies: The rodent studies cited on this page measured efficacy, not toxicity. They do not establish that Humanin is free of organ toxicity, immune effects, or cancer risk.
📊
IGF-1 Pathway Interaction: Humanin binds IGFBP-3, a regulator of IGF-1 activity (Ikonen et al., 2003). Long-term consequences of manipulating this axis in humans are unknown; IGF-1 dysregulation is associated with both neuroprotection and cancer promotion.
💉
Route of Administration: The cited animal studies gave Humanin or its analogs by intravenous, intracerebroventricular, or intraperitoneal injection, and Zhang et al. (2012) note an earlier intranasal study in mice. No route has been tested in humans.
⏰
Half-Life Uncertainty: Humanin's circulating half-life in humans is not well characterized. Dosing frequency and accumulation potential are unknown.
🏥
Regulatory Status: Not FDA approved. Not approved by EMA, TGA, or any major regulatory body. Classified as a research chemical. Not for human consumption under any approved protocol.
🚫
Contraindications (Theoretical): Hormone-sensitive cancers (due to IGF-1 axis involvement), pregnancy, pediatric use, and concurrent IGF-1 or insulin therapy are reasons to avoid it until clinical safety data exist.

Ideal Candidate Profile

Humanin research is most relevant for specific clinical contexts. Age-related neurodegeneration and metabolic dysfunction are the primary areas of interest.

✅ Potentially Relevant Research Context
  • Adults interested in longevity and mitochondrial health research
  • Research interest in Alzheimer's disease biomarker tracking
  • Metabolic syndrome with concurrent interest in mitochondrial function
  • Those following mitochondrial peptide research (MOTS-c, SS-31)
❌ Not Appropriate
  • Anyone with active or history of hormone-sensitive cancers
  • Currently pregnant or breastfeeding
  • Individuals on IGF-1 or insulin therapy
  • Anyone expecting clinical benefits (no human efficacy trials completed)
  • Those seeking a standalone Alzheimer's treatment

Important framing: Humanin is currently a research tool, not a therapeutic. The appropriate use is in clinical research contexts with proper oversight. Consumer use is premature given the current evidence base.

Key Study Citations

Study 1 — Discovery 2001
A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta
Hashimoto Y, Niikura T, Tajima H, Yasukawa T, et al. · Proc Natl Acad Sci USA · 2001
PMID: 11371646
Study 2 — Alzheimer's Model
S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice
Zhang W, Zhang W, Li Z, Hao J, et al. · Pharmacol Biochem Behav · 2012
PMID: 21993310
Study 3 — Aging & Insulin Sensitivity
Humanin: a novel central regulator of peripheral insulin action
Muzumdar RH, Huffman DM, Atzmon G, Buettner C, et al. · PLoS One · 2009
PMID: 19623253
Study 4 — Mitochondrial-Derived Peptides Review
MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism
Lee C, Kim KH, Cohen P · Free Radic Biol Med · 2016
PMID: 27216708
Study 5 — BAX Mechanism
Humanin peptide suppresses apoptosis by interfering with Bax activation
Guo B, Zhai D, Cabezas E, Welsh K, et al. · Nature · 2003
PMID: 12732850
Study 6 — IGFBP-3 Interaction
Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis
Ikonen M, Liu B, Hashimoto Y, Ma L, et al. · Proc Natl Acad Sci USA · 2003
PMID: 14561895
Study 7 — JAK2/STAT3 Review
Targeting the JAK2/STAT3 axis in Alzheimer's disease
Chiba T, Yamada M, Aiso S · Expert Opin Ther Targets · 2009
PMID: 19663649
Study 8 — Vascular Cells
Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress
Bachar AR, Scheffer L, Schroeder AS, Nakamura HK, et al. · Cardiovasc Res · 2010
PMID: 20562421

Key Takeaways

What We Know
  • First mitochondrial-derived peptide, discovered 2001
  • 24-amino acid sequence encoded in mtDNA (16S rRNA region)
  • Anti-apoptotic in cell studies: blocks BAX activation (Guo et al., 2003) and signals through JAK2/STAT3 (Chiba et al., 2009)
  • Reduces amyloid-beta toxicity in cell models; the synthetic analog S14G-humanin reduced amyloid pathology in mice
  • Circulating levels are lower in older humans and mice
  • Improved insulin sensitivity and lowered blood glucose in rodent studies
  • Circulates in blood; mitochondrial-derived peptides act as mitochondrial hormone-like signals (Lee et al., 2016)
What We Don't Know
  • No completed human Phase 2/3 clinical trials
  • Optimal dose, route, and frequency in humans not established
  • Long-term safety profile in humans unknown
  • Net effect of the Humanin–IGFBP-3 interaction on growth factor signaling
  • Whether supplemental Humanin actually reduces Alzheimer's risk in humans
  • Bioavailability and half-life in human circulation
  • Cancer risk implications of chronic IGF-1 axis modulation

Verified Research Source

Research compounds from Swiss Chems.

Browse Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost. Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify).

Supplements related to mitochondrial research.

Affiliate links support HighPeptides at no extra cost.

📚

Want the Complete Protocol Guide?

A broad reference to 20+ research compounds, all in one place.


Get the Guide: $19 (normally $29) →
The Peptide Buyer’s Playbook ($19)
Important Disclaimer

This page is for educational and informational purposes only. Humanin is a research peptide not approved by the FDA or any regulatory body. All data cited comes from preclinical studies (cell culture and animal models) and human observational data (circulating levels and blood-vessel tissue staining). No large human clinical trials have been completed. The safety and efficacy of Humanin in humans has not been established. Always consult a qualified, licensed healthcare provider before starting any new compound. Nothing on this page constitutes medical advice.

📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.